On The AIDS Front

Barron, Rachel
April 2007
Red Herring;4/30/2007, Vol. 4 Issue 16, p30
Trade Publication
The article focuses on the support needed by small private companies from venture capitalists to develop a cure for human immunodeficiency virus (HIV). Much remains to be done to improve treatment for the estimated 39.5 million people worldwide living with HIV. But it will not be easy for small private companies pinning their hopes on scarce venture support. Bruce Robertson of Atlanta, Georgia-based H.I.G. Ventures was among the few who took a chance on Metastatix, a startup based in Tucker, Georgia. The company is working on a drug to stop HIV from taking over one type of white-blood cell in the body's immune system. Founded in 2005, the startup has piled up $4 million after seed funding and one venture round.


Related Articles

  • Financings Roundup.  // BioWorld Today;11/28/2007, Vol. 18 Issue 230, p5 

    The article reports on the Series C financing closed by Clarus Therapeutics Inc. Clarus Therapeutics has closed a Series C financing led by H.I.G. Ventures, with participation from Thomas, McNerney & Partners. Clarus intends to use the funds to support Phase II development of OriTex oral...

  • Constellation's Series A Adds $32M for Epigenetics Platform. Boggs, Jennifer // BioWorld Today;4/30/2008, Vol. 19 Issue 84, p1 

    The article reports on the initial venture capital raised by start-up company Constellation Pharmaceuticals in April 2008. As reported, the proceeds will be used to build a preclinical pipeline of drug platform targeting epigenetic function. The names of the company's founders are given....

  • Apollo in 'A' $11.5M round.  // Medical Technology & Devices Week;10/15/2007, Vol. 5 Issue 41, p3 

    The article reports on the amount secured by Austin, Texas-based Apollo Endosurgery in a Series A financing round from PTV Science, H.I.G Ventures and individual investors. According to Lee Putman, vice president (VP) of market and development for Apollo, the fund will be used to help jump-start...

  • Apollo in 'A' $11.5 million round; Simplex Diabetic garners $50M. Ford, Omar // Medical Device Daily;10/9/2007, Vol. 11 Issue 193, p1 

    The article reports that Apollo Endosurgery has secured a Series A financing round. Apollo Endosurgery has received the financing round from PTV Sciences, H.I.G. Ventures and individual investors. This is the company's first substantial funding since receiving seed money from the University of...

  • A New Model for VC Funding? Paul Capital Bets $100M on It. Moran, Nuala // BioWorld International;1/13/2010, Vol. 15 Issue 2, p3 

    The article focuses on the decision of Paul Capital to provide roughly 100 million U.S. dollars to a new European company established to fund and conduct Phase III trials. It is noted that the move by the health care investor benefits companies that lack resources to advance products. The new...

  • Probiodrug Gets €36M for Novel Alzheimer's Program. Sheridan, Cormac // BioWorld International;11/4/2009, Vol. 14 Issue 44, p1 

    The article reports that Probiodrug AG raised more than 36 million euros in a Series B round to fund a new class of Alzheimer's disease drugs based on inhibiting glutaminyl cyclase (QC). The fund raised by the company has the potential to become the largest venture capital investment in...

  • Financings Roundup.  // BioWorld Today;1/13/2010, Vol. 21 Issue 8, p3 

    The article reports on the 5 million U.S. dollars in venture financing raised by BioLeap Inc. from Adams Capital Management and Quaker BioVentures. The funds will be used to finance continued development of the company's computational fragment-based drug design technology. Under the terms of the...

  • RetroVirox Building Antiviral Candidates for Others to Grow. Hollingsworth, Catherine // BioWorld Today;6/4/2010, Vol. 21 Issue 107, p1 

    This article focuses on the plan of San Diego, California-based RetroVirox Inc. to raise funds to support the hepatitis C virus (HCV) and other antiviral programs of the company. According to Juan Lama of RetroVirox, the focus of the firm is on the early stages of discovery and preclinical...

  • Probiodrug Acquires Ingenium For Stock, Raises $27.7M In Cash. Sheridan, Cormac // BioWorld International;6/27/2007, Vol. 12 Issue 26, p1 

    The article reports that Probiodrug AG has acquired Ingenium Pharmaceuticals AG in a stock-based deal and has closed a €20.6 million venture capital round. It reports that the move is intended to fund both an in-house drug development program in Alzheimer's disease and a newly acquired...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics